Tirzepatide vs Thymalin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tirzepatide
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.
Full details →Thymalin
Thymalin is a polypeptide preparation derived from calf thymus. Developed in Russia, it has been used for decades to support immune function and has shown potential anti-aging effects in long-term studies.
Full details →Side-by-Side Comparison
| Aspect | Tirzepatide | Thymalin |
|---|---|---|
| Mechanism | Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy. | Regulates the ratio of T-cell subpopulations, stimulates cellular immunity, and enhances phagocytosis. Also affects neuroendocrine regulation and may influence melatonin production. |
| Typical Dosage | Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks. | Clinical protocols: 5-20mg daily intramuscularly for 3-10 days. Often cycled 1-2 times per year for maintenance. |
| Administration | Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects. | Intramuscular injection. Usually administered in short courses rather than continuously. Often combined with Epithalamin for anti-aging protocols. |
| Side Effects | Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use. | Generally well-tolerated. May cause injection site reactions or temporary flu-like symptoms as immune function is modulated. |
| Best For |